Background. Recently in France, primary pulmonary hypertension developed in a cluster of patients exposed to derivatives of fenfluramine in appetite suppressants (N Engl J Med 1996;335: 609-16) 
Primary pulmonary hypertension (PPH), also called nearly forgotten. This was particularly apparent in a number of contemporary reviews of pulmonary artery unexplained pulmonary hypertension, is a rare disease with at least three different recognised histological prehypertension where the potential aetiological role of anorexigens was not mentioned. 8 9 sentations, 1 of which the so-called plexogenic arteriopathy is the most commonly encountered. The disease
The introductory article 10 reminds us that there is a recognised association between the intake of certain occurs with a predominance in young women, but incidence peaks have been noted also in children and appetite-suppressant drugs and the development of PPH.
11
in a geriatric population. 2 PPH is clinically characterised by non-specific symptoms of dyspnoea or cough and As stated, PPH is a rare disease and its incidence in any population group where an unusually high pretherefore is quite often initially misdiagnosed. Occasionally the first clinical presentation is with signs of valence has been established -for example, in patients with liver cirrhosis and portal hypertension or patients right heart failure. The median survival after diagnosis of PPH has been estimated to be 2.8 years.
3 Thus, in with AIDS -is still rather small. The most likely explanation is a low prevalence of a "pulmonary hypermany patients the disease takes a rapidly progressive very malignant course.
tension gene" or of a constellation of genetic factors. Given such a low prevalence of genetic predisposition, In recent years associations of plexogenic pulmonary arteriopathy have been found with portal hypertension 4 5 any trigger or expression factor will raise the number of patients with PPH to only a small extent. The introand with AIDS. Abenhaim (1996) that anorexigen use is currently the overwhelming cause of PPH, but if anorexigen use continues to increase, it is likely to become an increasingly important cause of PPH.
For the prospective International Primary Pulmonary November 1968, cases of aminorex-induced PPH were diagnosed for several years thereafter (box).
18
Hypertension Study (IPPHS) Group, 35 centres in France, Belgium, the Netherlands, and the UK agreed Symptoms consistent with PPH occurred 9-14 months after the start of the aminorex treatment, apto participate and to report cases of PPH diagnosed between September 1992 and September 1994. A total proximately one per 1000 aminorex users developed PPH, and the lesions of aminorex-induced PPH were of 95 patients with PPH were identified, 64 of whom had been reported by French centres. Definite use of histologically indistinguishable from those recognised in sporadic cases of PPH. 10 18 19 Gurtner 18 followed 71 anorexigens had been reported by 30 of the 95 patients with PPH but by only 26 of 355 controls. Although patients with aminorex-induced PPH and found that 34 patients had died (with a median survival of 3.5 the study was international in design, the data largely represented the French experience. Perhaps the most years). There was no clearcut relationship between the amount of the drug taken and mortality, but the risk striking finding of the IPPHS was that roughly 12% of the patients with PPH had taken anorexigens for 12 of developing aminorex-induced PPH increased with increased drug intake. 20 21 Attempts to induce pulmonary months or longer (compared with 0.6% in the control group). 10 hypertension by feeding aminorex to rodents, dogs, and cattle 19 22-24 failed, which would not be surprising if there is a specific human genetic susceptibility. The retrospective data analysis of the aminorex epidemic Anorexigens and PPH: the historical context Several medical centres in Switzerland, Austria, and also showed that approximately 10% of the patients with PPH had used aminorex in combination with Germany registered an increased incidence of severe pulmonary hypertension beginning in 1967, 12-17 roughly chlorphentermine, phenmetracine, or amphetamine.
Since the aminorex epidemic, sporadic cases of PPH 18 months after the anorexigen Menocil (aminorex fumarate) had been released in these three countries; related to the use of fenfluramine or phenformin have been reported. 25 by 1970 150 cases of PPH associated with aminorex use had been reported. 17 The 1985 review by Gurtner 18 concluded that altogether 582 cases of aminorexinduced PPH had been reported. The early experience Anorexigen-associated pulmonary hypertension: the pharmacological context with this epidemic in Vienna (fig 1) illustrates the latency period between the time of introduction of the drug
The exact pathogenetic events leading to the manifestation of PPH are still unknown. It appears, however, and the time when an increased incidence of PPH was recognised (the drug had been released in December that for the anorexigen-associated cases of PPH, 5-hydroxytryptamine (5-HT, serotonin) might be a com-1965). Although the drug was taken off the market in mon denominator. Figure 2 shows the structures of some of the anorexigens, including aminorex, and also the frequently used antidepressant agents such as sertraline hydrochloride and fluoxetine hydrochloride. All of these agents release 5-HT from storage sites or inhibit uptake of 5-HT, or both. Although aminorex resembles amphetamine and has been shown to release noradrenaline (norepinephrine), aminorex also releases 5-HT. Gahl and coworkers 14 found no increase in levels of metabolites of 5-HT in the urine of patients with aminorex-induced PPH. However, these measurements were conducted many months after the aminorex intake. Nevertheless, a unifying hypothesis operating with a 5-HT paradigm may be justified at the present time.
Herve and coworkers reported the case history of a patient with PPH and a platelet storage disorder 26 and, more recently, described the plasma 5-HT levels in patients with PPH. 27 Of great interest is their finding platelets. Moreover, this increase in plasma levels of 5- HT persisted in those patients who had received lung PPH is probably more complex, as evidenced by the absence of reports of a relationship between the chronic transplantation. If this finding of raised levels of 5-HT in patients with PPH can be confirmed in other intake of antidepressants such as fluoxetine hydrochloride (a very widely used drug) and PPH. However, populations with PPH, it would be tempting to speculate that agents which alter the metabolism of 5-HT could in our centre we have recently diagnosed PPH in a woman who had not taken anorexigens but had been be trigger factors for PPH (figs 3 and 4).
It is clear from experimental data that 5-HT does, treated for her depression with sertraline hydrochloride (unpublished observation). indeed, cause pulmonary vasoconstriction 28 and produces both hyperplasia and hypertrophy of isolated cultured pulmonary artery smooth muscle cells. 29 30 This proliferative effect of 5-HT is apparently transduced through the 5-HT2 receptor. 30 However, the relationship between alteration in 5-HT metabolism and group.bmj.com on October 14, 2017 -Published by http://thorax.bmj.com/ Downloaded from S66 Voelkel LEARNING POINTS * Appetite suppressants which affect the release or uptake of 5-HT (serotonin) may be trigger factors for primary pulmonary hypertension (PPH) in a genetically susceptible segment of the general population. * Primary pulmonary hypertension is a generally fatal disease of young women, a group more likely to take appetite suppressants than men. * There may or may not be an association between obesity itself and the development of PPH but PPH does occur in non-morbidly obese users of appetite suppressants. * Development of dyspnoea, fatigue and cough in anorexigen users (particularly when these symptoms occur in spite of weight loss) is a reason for alarm and should trigger investigation for pulmonary hypertension.
Anorexigen-associated pulmonary hypertension they need to achieve their weight loss goal and they should continue to take the drug to maintain their and obesity: risk-benefit ratio It should be clear from the above that anorexigens weight loss" (May 1996). All this is worrisome when one considers that the can cause pulmonary hypertension. It should also be appreciated that many patients are looking for a pharpharmaceutical industry does not generally screen new compounds for their potential to cause pulmonary macological solution to their obesity problem. In the USA dieting and weight management are a multibillion hypertension. By contrast, drugs do not usually reach the market if they raise the systemic blood pressure. dollar industry. Hundreds of new diet pill clinics have opened during the last year. Presently we have no good
Given the uncertainty of currently available "diet pills" to cause successful long term weight loss 25 34 35 and the understanding of the relationship between body weight and pulmonary hypertension -apart from the well risk of developing a lethal disease, the risk-benefit ratio could be considered unacceptably high. The introknown association of the obesity/hypoventilation/polycythaemia syndrome and pulmonary hypertension. ductory article has lessened previous uncertainty and, as the number of anorexigen users in the USA apGurtner, summarising his experience of 71 patients with presumed anorexigen-induced PPH, 18 found that proaches 20 million, we may soon witness a much greater incidence of PPH in that country as in Europe, 50% of the patients had used aminorex while being only mildly overweight (110% of ideal body weight). While anywhere from 400 to 1000 additional new cases of PPH per year. the normal incidence of PPH is about 1.2 cases per one million population/year, the risk of developing PPH for non-overweight users of dexfenfluramine has been users at 55 per million/year. 32 This implies that obesity
